Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11802152 Methods of treating FGF21-associated disorders

Patent 11802152 was granted and assigned to Novartis on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Novartis
Novartis
Date Filed
December 1, 2021
Date of Patent
October 31, 2023
Patent Applicant
Novartis
Novartis
Patent Application Number
17539335
Patent Citations
‌
US Patent 9085626 FGFR1 agonists and methods of use
‌
US Patent 8372952 Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
‌
US Patent 8697369 Method for screening a test substance for activating a receptor associated with FGF 21 activity
‌
US Patent 8722622 FGF21 conjugates and anti-diabetic uses thereof
‌
US Patent 9006400 Fibroblast growth factor-21-Fc fusion proteins
‌
US Patent 9284378 Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
Patent Inventor Names
Brian Boettcher
Fangmin Xu
Regis Cebe
David Langdon Yowe
Guochun Li
Shari Lynn Caplan
John A. Taraszka
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11802152
Patent Primary Examiner
‌
Marianne P Allen

Find more entities like US Patent 11802152 Methods of treating FGF21-associated disorders

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo